PT  - JOURNAL ARTICLE
AU  - Sariol, Carlos A.
AU  - Pantoja, Petraleigh
AU  - Serrano-Collazo, Crisanta
AU  - Rosa-Arocho, Tiffany
AU  - Armina, Albersy
AU  - Cruz, Lorna
AU  - Stone, E. Taylor
AU  - Arana, Teresa
AU  - Climent, Consuelo
AU  - Latoni, Gerardo
AU  - Atehortua, Dianne
AU  - Pabon-Carrero, Christina
AU  - Pinto, Amelia K.
AU  - Brien, James D.
AU  - Espino, Ana M.
TI  - Function is more reliable than quantity to follow up the humoral response to the Receptor Binding Domain of SARS-CoV-2 Spike protein after natural infection or COVID-19 vaccination
AID  - 10.1101/2021.06.02.21257975
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.06.02.21257975
4099  - http://medrxiv.org/content/early/2021/08/10/2021.06.02.21257975.short
4100  - http://medrxiv.org/content/early/2021/08/10/2021.06.02.21257975.full
AB  - Both the SARS-CoV-2 pandemic and emergence of variants of concern have highlighted the need for functional antibody assays to monitor the humoral response over time. Antibodies directed against the spike (S) protein of SARS-CoV-2 are an important component of the neutralizing antibody response. In this work, we report that in a subset of patients—despite a decline in total S-specific antibodies—neutralizing antibody titers remain at a similar level for an average of 98 days in longitudinal sampling of a cohort of 59 Hispanic/Latino patients exposed to SARS-CoV-2. We also report that serum neutralization capacity correlates with IgG titers, wherein IgG1 was the predominant isotype (62.71%), followed by IgG4 (15.25%), IgG3 (13.56%), and IgG2 (8.47%) at the earliest tested timepoint. IgA titers were detectable in just 28.81% of subjects, and only 62.71% of subjects had detectable IgM in the first sample despite confirmation of infection by a molecular diagnostic assay. Our data suggests that 100% of seroconverting patients make detectable neutralizing antibody responses which can be quantified by a surrogate viral neutralization test. Examination of sera from 10 out of the 59 subjects which had received an initial first dose of mRNA-based vaccination revealed that both IgG titers and neutralizing activity of sera were higher after vaccination compared to a cohort of 21 SARS-CoV-2 naïve subjects. One dose was sufficient for induction of neutralizing antibody, but two doses were necessary to reach 100% surrogate virus neutralization in subjects irrespective of previous SARS-CoV-2 natural infection status. Like the pattern seen after natural infection, after the second vaccine dose, the total anti-S antibodies titers declined, however, neutralizing activity remained relatively constant for more than 80 days after the first vaccine dose. The decline in anti-S antibody titer, however, was significantly less in pre-exposed individuals, highlighting the potential for natural infection to prime a more robust immune response to the vaccine. Furthermore, our data indicates that—compared with mRNA vaccination—natural infection induces a more robust humoral immune response in unexposed subjects. However, this difference was significant only when neutralizing antibody titers were compared among the two groups. No differences were observed between naturally infected and vaccinated individuals when total anti-S antibodies and IgG titers were measured. This work is an important contribution to understanding the natural immune response to the novel coronavirus in a population severely impacted by SARS-CoV-2. Furthermore, by comparing the dynamics of the immune response after the natural infection vs. the vaccination, these findings suggest that a functional neutralizing antibody tests are more relevant indicators than the presence or absence of binding antibodies. In this context, our results also support standardizing methods of assessing the humoral response to SARS-CoV-2 when determining vaccine efficacy and describing the immune correlates of protection for SARS-CoV-2.Competing Interest StatementThe authors have declared no competing interest.Funding StatementAuthors want to thank the volunteers that were willing to participate and to contribute to science. To Ilia Toledo, MT, Francheska Rivera, MT and Drs. Ivelisse Martin for their contribution and diligent efforts to provide access to the samples from some presumptive-positive subjects exposed to SARS-CoV-2. Particular acknowledgement is deserved for all administrative and supportive staff at the Medical Sciences Campus, University of Puerto Rico, Laboratorio Clinico Toledo, Laboratorio, Clinico Martin, Banco de Sangre Centro Medico and Banco de Sangre Servicios Mutuos for their availability and commitment during the curfew imposed by the quarantine period. Thanks also to the Latin clinical Trial Center staff for their dedication providing excellent care to the participants. The Puerto Rico Science Technology and Research Trust supported research reported in this work under agreement number 2020-00272 to AME and CAS. Also, the University of Puerto Rico contributed with the UPR-COVID-19 Grant to CAS and AME. This work was also supported by 1U01CA260541-01 to CAS (NCI/NIAID). This work was also partiallly funded by Saint Louis University COVID-19 research Seed Funding to awarded to AKP and awarded to JDB.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All volunteers (> 21 years old) are participating in the IRB approved clinical protocol Molecular Basis and Epidemiology of Viral infections circulating in Puerto Rico, Pro0004333. Protocol was submitted to, and ethical approval was given by Advarra IRB on April 21, 2020. An Informed Consent Form and a study questionnaire also approved by the IRB were administered to the volunteers. Plasma donors were self-enrolled and were amply verbally informed about the relevance of their participation as plasma donors for the treatment of COVID-19 patients. They were also given the opportunity to ask questions. Furthermore, they were handled throughout the standard blood donors protocols signing the Blood Banks standard consent with ample information about the use of their samples for research purposes only. In addition, before receiving the samples from these sources the subjects data that has been stripped of all identifiers so that the information cannot be traced back to an individual. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll additional data collected during this study is available as supplementary information